Thrombophilia, thromboembolism and the use of the unfractionated and low-molecular-weight heparins;Trombofilia, tromboembolia y el uso de las heparinas no fraccionadas y de bajo peso molecular

Revista de Investigacion Clinica

Volumn 52, Issue 5, 2000, Pages 529-545

  Lobato Mendizábal, Eduardo ^a,b   Majluf Cruz, Abraham ^c  

^a Hospital Universitario de Puebla   (Mexico)

^b CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^c Hospital General Regional Gabriel Mancera   (Mexico)

Author keywords

Embolism; Heparins; Thrombogenesis; Thrombophilia; Thrombosis

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ALGORITHM; ANTICOAGULATION; DIAGNOSTIC PROCEDURE; DRUG CHOICE; DRUG INDICATION; HUMAN; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0034533219     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (274)

1. Shafer A. The hipercoagulable states. Ann Intern Med 1985; 102: 814-28.
2. Izaguirre R. Mecanismos hemostáticos. En: Ruiz G, Ed. Fundamentos de Hematología: Editorial Médica Panamericana, 1994: 190-204.
3. Izaguirre AR, De la Peña DA. Estados Pre-trombóticos. En Manual de Trombosis y Hemostasia. Martínez-Murillo C, Quintana GS (ed.). Ed. Prado, 1996: 333-50.
4. Majluf CA. Mecanismos hemostáticos. En fundamentos de hematología, GJ Ruiz Argüelles (ed.). Ed. Med. Panamericana, 1998: 264-288.
5. Nygaard K, Brown G. Essential thrombophilia. Report of five cases. Arch Int Med 1937; 59: 82-106.
6. Scazziota A, Altman R. El mecanismo de la hemostasia normal. Rev Iberoamer Trom Hemost 1994; 7: 95-109.
7. Lobato-Mendizábal E, Ruiz-Argüelles GJ. Proteína C, proteína S y trombomodulina: uno de los mecanismos antitrombóticos naturales. Rev Invest Clin Mex 1990; 42: 54-62.
8. Angle E. Overview on fibrinolysis: Plaminogen activation pathways on fibrin and cell surfaces. Chem Physc Lipids 1994; 67/68: 353-62.
9. Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulability: Congenital and acquired thrombophilias. Clin Appl Thrombosis/Hemostasis 1998; 4: 25-50.
10. Girolami A, Simioni P, Zanardi S et al. The hereditary thrombosis. Rev Iberoamer Trom Hemost 1993; 6: 113-17.
11. Ruiz-Argüelles GJ, Garcés-Eisele J, Alarcón-Segovia D, Ruiz-Argüelles A. Activated protein C resistence phenotype and genotype in patients with primary antiphsopholipid syndrome. Blood Coag Fibrinol 1996; 7: 344-8.
12. Rocha E. Estados trombofílicos congénitos. Programa Educativo. XXXIX Jornada AMEH 1999; 139-42.
13. Schroeder W, Koessling M, Wulff K, Wehnert M, Hermann FH. World distribution of factor V Leiden mutation. Lancet 1996; 347: 58-9.
14. Ruiz-Argüelles GJ. Contribuciones mexicanas al conocimiento de las alteraciones trombogénicas en el síndrome de anticuerpos anti-fosfolípidos. Rev Iberoamer Tromb Hemostasia 1997; 10: 69-71.
15. Otero AM, Novoa JE, Steffano B, Zucchi A, Cotic G, De Bellis R. Enfermedad tromboembólica en una población de 200 pacientes jóvenes. Estudio cooperativo nacional. Rev Iberoamer Trom Hemost 1995; 8: 70-3.
16. González AM. Trombofilias secundarias. Programa Educativo. XXXIX Jornada anual de la AMEH 1999; 189-90.
17. Rosendaal FR. Venous thrombosis: a multicasual disease. Lancet 1999; 353: 1167-73.
18. Césarman G, Villazón S, Zuñiga J et al. Absence of factor V Leiden mutation in Mazateco Indians: A polymorphism of recent acquisition in the Americas. Int J Haematol 1996; 64: (suppl. 1): S111.
19. Ruiz-Argüelles GJ. Avances recientes en trombofilia. Gac Med Mex 1996; 132: 289-293.
20. Ruiz-Argüelles GJ. Resistencia a la proteína C activada como causa de trombofilia. Rev Invest Clin Mex 1996; 48: 223-229.
21. Yin E. Effect of heparin on the neutralization of factor Xa and thrombin by plasma alpha-2-globulin inhibitor. Trom Diat Hemorr 1975; 33: 43.
22. Goldhaber S, Savage D, Garrison R et al. Risk factors for pulmonary embolism: The Framingham Study. Am J Med 1983: 74: 1023-28.
23. Carter C, Gent M, Leclerc J. The epidemiology of venous thrombosis. In: Colman RW, Hirsh J, Marder V et al, Ed. Hemostasis and Thrombosis. Philadelphia: JB Lippincott, 1987; 76: 1185-98.
24. Sobel M, McNeill PM, Carlson PL, Kermode JC et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793.
25. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643.
26. rd Ed. Philadelphia: JB Linppincott 1992: 837-60.
27. Hirsh J, Fuster V. Guide to anticoagulant therapy: heparin. Circulation 1994; 89: 1449-68.
28. Hirsh J, Raschke R, Warkentin T, Dalen J et al. Heparin: Mechanism of action, pharmakocinetics, dosing considerations, monitoring, efficacy and safety. Chest 1995; 108: 2585-2755.
29. Clagett G, Anderson F, Het J, Levine M et al. Prevention of venous thromboembolism. Chest 1995; 108: 3125-334.
30. Hyers T, Hull R, Weg J. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108: 3355-3515.
31. Cairns J, Lewis D, Meade T et al. Antithrombotic agents in coronary artery disease. Chest 1995; 108: 3805-4005.
32. Soto A, Frías J. Farmacología clínica de las heparinas de bajo peso molecular. Rev Iberoamer Trom Hemos 1995; 8: 3-10.
33. Izaguirre AR, Saucedo MJ. Tratamiento antitrombótico. En Manual de Trombosis y Hemostasi. Martinez-Murillo C, Quintana GS (ed.). Ed. Prado 1996: 363-92.
34. Amiral J. Molecular markers in thrombosis and hemostasis. Clin Appl Thrombosis/Hemostasis 1997; 3: 71-81.
35. De Estefano V, Finazzi G, Manucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
36. Engesser L, Brokmans AW, Briet E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: Clinical manifestation. Ann Intern Med 1987; 106: 677-82.
37. Heijboer H, Brandjes DPM, Buller HR, Sturk APH, Ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with DVT. N Engl J Med 1990; 29: 1512-16.
38. Dahlback B, Carlsson M, Svensson PJ. Familiar thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
39. Bertina RM, Reitsma PH, Rosendhal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as a risk factor for vein thrombosis. Thromb Haemostas 1995; 74: 449-53.
40. Gensini GF, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism. Sem Thromb Hemostas 1997; 23: 55-67.
41. Bick RL. The antiphospholipid thrombosis syndrome: A common multidisciplinary medical problem. Clin Appl Thrombosis/Hemostasis 1997; 3: 270-83.
42. Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: An analysis of 1274 surgical patients. Br J Surg 1985; 72: 105-8.
43. Clagett GP, Reish JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-40.
44. Becker J, Schampi B. The incidence of postoperative venous thrombosis of the legs. Acta Chir Scand 1973; 139: 357-67.
45. Mayo M, Halil T, Browse NL. The incidence of deep vein thrombosis after prostatectomy. Br J Urol 1971; 43: 738-42.
46. Nicolaides AN, Field ES, Kakkar VV, Yates-Bell AJ, Taylor S, Clarke MB. Rostatectomy and deep-vein thrombosis. Br J Surg 1972; 59: 487-88.
47. The report of the national confidential inquiry into perioperative deaths 1990. Lincoln's Inn Fields, London, Apr. 1992: 35-43.
48. Malone KM. Coronary artery bypass grafting. In: Goldhaber SZ ed. Prevention of venous thromboembolism. Marcal Dekker, New York, 1993: 439-44.
49. Cohen AT, Kakkar VV. Prevention of venous thromboembolism in general surgery. In: Hull R, Pineo GF, Eds. Disorders of thrombosis. Saunders, Philadelphia, 1966: 200-8.
50. Gross JS, Neufeld RR, Lobow LS, Gerber I, Rodstein M. Autopsy studies of the elderly institutionalized patients: Review of 234 autopsies. Arch Intern Med 1988; 148: 173-176.
51. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302: 709-11.
52. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50.
53. Kierkegaard A, Norgren L, Olsson CG, Castenfors J, Persson G, Persson S. Incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 1987; 222: 409-14.
54. Anderson FA, Wheeler B, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660-4.
55. Anderson DR, Wells PS, Stiel I, MacLeod B, Simms M, Gray L, Robinson KS, Bormanis J, Mitchell M, Lewandowski B, Flowerdew G. Thrombosis in the emergency department. Use of clinical diagnosis model to safely avoid the need for urgent radiological investigation. Arch Intern Med 1999; 159: 477-82.
56. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler J, Segrestaa JM. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: An randomized double blind trial. Haemostasis 1986; 16: 159-64.
57. Thromboembolic risk factors consensus group: Risk of an prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567-74.
58. th World Congress of the International Union of Angiology. London, 1995.
59. Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; 2: 910-12.
60. Crandon AJ, Peel KR, Anderson JA, Thompson A, McNicol GP. Prophylaxis of postoperative deep vein thrombosis: Selective use of low-dose of heparin in high-risk patients. Br Med J 1980; 2: 345-7.
61. Racoczi I, Chamone D, Collen D, Verstraete H. Prediction of postoperative leg-vein thrombosis in gynecological patients. Lancet 1978; 1: 509-10.
62. Sue-Ling HM, Johnstone D, McMahon MJ, Philips PR, Davies JA. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet 1986; 1: 1173-6.
63. Lowe GD, Osborne DH, McHardle BM, Smith A, Carter DC, Forbes CD, McLaren D, Prentice CR. Prediction and prophylaxis of venous thrombosis in elective gastrointestinal surgery. Lancet 1982; 1: 409-12.
64. Rocha E, Alfaro MJ, Paramo JA, Canadell JM. Preoperative identification of patients at high risk of deep venous thrombosis despite prophylaxis in total hip replacement. Thromb Haemostas 1988; 59: 93-5.
65. Bick RL, Fareed J. Current status of thrombosis: A multidisciplinary medical issue and major American health problem-Beyond the year 2000. Clin Appl Thrombosis/Hemostasis 1997; 3 (Suppll): S1-S5.
66. Hughes GVR, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-89.
67. Bick RL. Antiphospholipid-thrombosis syndrome: Etiology, pathophisiology, diagnosis and management. Internat J Hematol 1997; 65: 193-213.
68. Bick RL, Laughlin HR, Cohen B et al. Fetal wastage syndrome due to blood protein/plateles defects: Results of prevalence studies and treatment outcome with low-dose heparin and low-dose aspirin. Clin Appl Throm Hemost 1995; 1: 286-88.
69. Derue G, Englert H, Harris E. Fetal loss in systemic lupus: Association with anticardiolipin antibodies. Br J Obstet Gynecol 1985; 5: 207-09.
70. Carreras L, Defren G, Manchin S. Arterial thrombosis, intrauterine death and lupus anticoagulant: Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-46.
71. Prandoni P, Lensing AWA, Prins MR. The natural history of deepvein thrombosis. Sem Thromb Haemostas 1997; 23: 185-8.
72. Hyers TM. Diagnosis of pulmonary emboli. Thorax 1995; 50 930-32.
73. Lensing AWA, Prandoni P, Brandjes D et al. Detection of deep vein thrombosis by real time B-mode ultrasonography. N Engl J Med 1989; 320: 342-45.
74. Wells PS, Hirsh J, Anderson DR et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345: 1326-30.
75. Agnelli G, Volpato R, Radiacchia S et al. Detection of asymptomatic deep vein thrombosis by real-time B-mode ultrasonography in hip surgery. Thromb Haemost 1992; 68: 257-60.
76. Perrier A, Bounameaux H, Morabia A et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-dimer levels, and ultrasonography: a management study. Arch Intern Med 1996; 156: 531-36.
77. Hull RD, Hirsh J, Sackett DT et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation 1981; 64: 622-25.
78. Hull RD, Hirish J, Sackett Dl et al. Replacement of venography in suspected venous thrombosis by impedance plethysmography and 125 I-fibrinogen leg scanning. Ann Intern Med 1981; 94: 12-5.
79. Huisman MV, Büller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314: 823-28.
80. Hirsh J. Reliability of non-invasive test for the diagnosis of venous thrombosis. Thromb Haemost 1991; 65: 221-22.
81. Lensing AWA, Büller HR, Prandoni P et al. Contrast venography, the gold standard for the diagnosis of deep vein thrombosis: improvement in observer agreement. Thromb Haemostat 1992; 67: 8-12.
82. Lensing AWA, Hirsh J. I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Throm Haemost 1993; 69: 2-7.
83. Cogo A, Lensing AWA, Parandoni P et al. Failure of thrombin antithrombin II complexes in the diagnosis of deep vein thrombosis. Angiology 1991; 43: 975-79.
84. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost 1994; 71: 1-6.
85. Wells PS, Brill-Edwards P, Stevens P et al. A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation 1995; 91: 2184-87.
86. Goldhaber SX, Simons GR, Elliott Cg et al. Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 1993; 270: 2819-22.
87. De Moerloose P, Desmarais S, Bounameaux H et al. Contribution of a new, rapid, individual, and quantitative automated D-dimer ELISA to exclude pulmonary embolism. Thromb Haemostat 1996; 75: 11-3.
88. Stein PD, Hull RD, Saltzman HA, Pineo G. Strategy for diagnosis of patients with suspected acute pulmonary embolism. Chest 1993; 103: 1553-59.
89. Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129: 997-1005.
90. Büller HR, Lensing AWA, Hirsh J et al. Deep vein thrombosis: new non-invasive diagnostic test. Thromb Haemost 1991; 66: 133-.
91. Hull RD, Hirsh J, Carter CJ et al. Diagnostic value of ventilation perfusion scanning in patients with suspected pulmonary embolism. Chest 1985; 88: 819-28.
92. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753-59.
93. Ginsberg JS, Wells PS, Hirsh J et al. Re-evaluation of the sensitivity of impedance plethysmography for the detection of proximal deep vein thrombosis. Arch Intern Med 1994; 154: 1930-33.
94. Ginsberg JS, Brill-Edwards PA, Demers C, Donovan D, Panju A. D-dimer in patients with suspected pulmonary embolism. Chest 1993; 104: 1679-84.
95. Borg JY, Levesque H, Cailleux N et al. Rapid quantitative D-dimer assay and clinical evaluation for the diagnosis of clinically suspected deep vein thrombosis. Thromb Haemost 1997; 77: 602-3.
96. Wells PS, Brilledwards P, Stevens P et al. Novel and rapid wholwblood assay for D-dimer in patients with clinically suspected DVT. Circulation 1995; 91: 2184-7.
97. Rocha E. Abordaje diagnóstico de la trombosis. Programa Educativo. XXXIX Jornada anual de la AMEH 1999; 190-1.
98. Stein PD, Hull RD, Pineo G. Strategy that includes noninvasive leg test for diagnosis of thromboembolic disease in patients with suspected acute pulmonary embolism based on data from PIOPED. Arch Intern Med 1995; 155: 2101-4.
99. Fareed J. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development. Clin Appl Thrombosis/Hemostasis 1998; 4: 227-37.
100. Rak K. Heparin Therapy: 1998 (current use of the 80-year-old heparin). Orv Hetil 1999; 140: 59-66.
101. Salzman EW, Deykin D, Shapiro RM, Rosemberg R. Management of heparin therapy: Controlled prospective trial. N Engl J Med 1975; 292: 1046-50.
102. Hull R, Raskob G, Hirsh J, Jay R, Leclerc J, Geerts W, Rosenbloom D, Sacket D, Anderson CH, Harrison L, Gent M. Continuous intravenous heparin compared whit intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
103. Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene D. Dosage, anticoagulant and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Sem Thromb Hemostas 1997; 23: 83-90.
104. Hull RD, Pineo GF. Editorial Overview: Controversies in anticoagulant therapy. Clin Appl Thrombos Hemostas 1997; 3 (Suppl. 1): S6-S7.
105. Pineo GF, Hull RD. Low-molecular-weight heparin: Prophylaxis and treatment of venous tromboembolism. Annu Rev Med 1997; 48: 79-91.
106. Lane DA. Heparin binding and neutralizing protein. In Heparin, chemical and biological properties. Clinical Applications, ed. DA Lane, U Lindahl London Edwars Arnol. 1989; 189: 363-91.
107. Kandrotas RJ. Pharmacology and pharmacokinetics of antithrombotic agents. Clin Appl Thrombosis/Hemostasis 1997; 3: 157-64.
108. Lindahl U, Thunberg L, Backstrom G et al. Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 1984; 259: 12368-76.
109. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979; 76: 1218-22.
110. Casu B, Oreste P, Torri G et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Biochem J 1981; 197: 599-609.
111. Weitz JI, Hudoba M, Messel D et al. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
112. Salzman EW, Rosenberg RD, Smith MH et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
113. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-69.
114. Hoppensteadt D, Walenga JM, Fasanella A et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and low molecular weight heparin. Thromb Res 1995; 77: 175-85.
115. Barzu T, Molho P, Tobelem G et al. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Haematol 1984; 26: 243-47.
116. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 1989; 556: 245-54.
117. Bara L, Billaud E, Grammond G et al. Comparative pharmacokinetics of low molecular weight heparin (PK10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-36.
118. Levine M, Hirsh J, Gent M et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
119. Fennerty A, Thomas P, Blackhouse G et al. Audit of control of heparin treatment. Br Med J 1985; 290: 27-8.
120. Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep-venous thrombosis. Arch Intern Med 1988; 148: 1321-25.
121. Cruickshank MK, Levine MN, Hirsh J et al. A standard nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-37.
122. Hull RD, Raskob GE, Rosenbloom DR et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-95.
123. Gabel A, Müller S. Fatal hematoma during treatment with adjusted-dose subcutaneous heparin therapy. N Engl J Med 1999; 340: 61-2.
124. Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-60.
125. Warkentin TE, Kelton JG. Heparin induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1-34.
126. Boshkov LK, Warkentin TE, Hayward CPM et al. Heparin induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8.
127. Kelton JG, Sheridan D, Brian H et al. Clinical usefulness of testing for a heparin -dependent platelet aggregation factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984; 103: 606-12.
128. Arepally G, Reynolds C, Tomaski A et al. Comparison of PF4/heparin ELISA assay with the 14-C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648-54.
129. Wallis DE, Lewis BE, Messmore H, Wehrmacher WH. Heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thrombosis/Hemostasis 1998; 4: 160-3.
130. Greinacher A, Vyolpel H, Janssens U, Heach-Wunderle V, Kemkes-Matthes B, Eichler P, Muller-Veiten HG, Pyotzsch B. Recombinant Hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
131. Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am 1998; 82: 635-58.
132. Wang LC, Huhle G, Malsch R, Hoffmann V, Song XL, Harenberg J. Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II. Eur J Clin Invest 1999; 29: 232-7.
133. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol 1999; 36 (suppl. 1): 7-11.
134. Poullin P, Pietri PA, Lefevre P. Heparin-induced thrombopenia: rapid regression of thrombopenia and thrombosis after plasma exchange. Case report. Rev Med Intern 1998; 19: 819-22.
135. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-88.
136. Prandoni P, Lensing AW, Buller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441-45.
137. Lopaciuk S, Meissner AJ, Filipecki S et al. Subcutaneous low-molecular-weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicentre trial. Thromb Haemost 1992; 68: 14-8.
138. Simonneau G, Charbonnier B, Decousus H et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Inter Med 1993; 153: 1541-6.
139. Lindmarker P, Holmstrom M, Granqvist S et al. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1994; 72: 186-90.
140. Valentine KA, Hull DR, Pineo GF. Low-molecular-weight heparin therapy and mortality. Sem Thromb Hemostas 1997; 23: 173-8.
141. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22-36.
142. Engelberg H. Actions of heparin that may affect the malignant process. Cancer 1999, 85: 257-72.
143. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. Am J Clin Oncol 1999; 22: 187-90.
144. Pilati PL, Rossi CR, Mocellin S, Pozzobon M, Galeotti F, Foletto M, Scalerta R, Scagnet B, Alaggio R, Lise M. Isolated vascular perfusion of human colon with adenocarcinoma. World J Surg 1999; 23: 197-201.
145. Andersson LO, Barrowcliffe TW, Holmer E et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III by gel filtration. Thromb Res 1976; 9: 575-83.
146. Thunberg J, Lindhal U, Tengblad A et al. On the molecular weight dependence of the anticoagulant activity of heparin. Biochem J 1979; 181: 241-43.
147. Lindahl U, Bäckström G, Höök M, Thunbrg L, Fransson LA, Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 1979; 76: 3198-202.
148. Bianchini P, Liverani L, Mascellani G, Parma B. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes. Semin Thromb Hemostas 1997; 23: 3-10.
149. Lindahl U, Bäckström G, Thunbrg L, Leder IG. Evidence for the 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980; 77: 6551-55.
150. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
151. Fareed J, Walenga JM, Hoppensteadt D et al. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988; 18 (Suppl.3): 3-15.
152. Ara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988; 543: 65-72.
153. Briant L, Caranobe C, Saivin S et al. Unfractionated heparin and CY216. Pharmacokinetics and bioavailabilities of the anti-factor Xa and Iia. Effects of intravenous and subcutaneous injection in rabbits. Thromb Haemost 1989; 61: 348-53.
154. Anderson L-O, Barrowcliffe TW, Holmer E et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 115: 531-8.
155. Fareed J, Walenga JM, Racanelli A et al. Validity of the newly established low molecular weight heparin standard in cross referencing low molecular weight heparin. Haemostasis 1988; 3: 33-47.
156. Barrowcliffe TW, Curtis AD, Johnson EA et al. An international standard for low molecular weight heparin. Thromb Haemost 1988; 60: 1-7.
157. Holmer E, Soderberg K, Bergqvist D et al. Heparin and its low molecular weight derivates: anticoagulant and antithrombotic properties. Haemostasis 1986; 16 (Suppl 2): 1-7.
158. Carter CJ, Kelton JG, Hirsh J et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982; 59: 1239-45.
159. Matzsch T, Bergqvist D, Hedner U et al. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rates. Thromb Haemost 1990; 63: 505-9.
160. Boneu B, Buchanan MR, Cade JF et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985; 40: 81-9.
161. Andriuoli G, Mastacchi R, Barnti M et al. Comparison of the antithrombotic and hemorrhagic effects of heparin and new low molecular weight heparin in the rat. Haemostasis 1985; 15: 324-30.
162. Lensing AW, Prins MH, Davidson BL et al. Treatment of deep venous thrombosis with low-molecular-weight heparin. Arch Intern Med 1995; 155: 601-7.
163. Monreal M, Lafoz E, Salvador R et al. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol 1989; 37: 415-18.
164. Monreal M, Vinas L, Monreal L et al. Heparin-relates osteoporosis in rats. A comparative study between unfractionated heparin and a low molecular weight heparin. Haemostasis 1990; 20: 204-7.
165. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-73.
166. Warkentin TE, Levine MN, Hirsh J et al. Heparin induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5.
167. Cade JF, Buchanan MR, Boneu B. A comparison of the antithrombotic and hemorrhagic effects of low-molecular-weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-25.
168. Forestier F, Daffos F, Capella-Pavlvosky M. Low molecular weight heparin (PH 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557-60.
169. Andrew M, Cade J, Buchanan MR et al. Low-molecular-weight heparin does not cross the placenta. Thromb Haemost 1983; 50: 225.
170. Omri A, Delaloye FJ, Andersen H et al. Low-molecular-weight heparin, Novo LHN-1 does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989; 61: 55-6.
171. Melissari E, Parker CJ, Wilson NV et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-6.
172. Sturridge F, de Swiet M, Letsky E. The use of low molecular weight heparin for thomboprophylaxis in pregnancy. Br J Obstet Gynecol 1994; 101: 69-71.
173. Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 european clinics. Haemostasis 1994; 24: 55-6.
174. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995; 108: 305.
175. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. New Engl J Med 1996; 335: 108-14.
176. Strekerud FG, Abilgaard U. Heparin and low molecular weight heparin prolong prothrombin times in patients on warfarin treatment. Clin Appl Thrombosis/Hemostasis 1998; 4: 189-95.
177. Girolami B, Prandoni P, Rossi L, Girolami A. Transaminase elevation in patients treated with unfractionated heparin or low molecular weight heparin for venous thromboembolism. Clin Appl Thrombosis/Hemostasis 1998; 4: 126-8.
178. Litin SC, Heit JA, Mees KA. Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions. The thrombophilia Center Investigators. Mayo Clin Proc 1998; 73: 545-50.
179. Kakkar VV, Murray WJG. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-91.
180. Kakkar VV, Cohen AT, Edmonson RA et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
181. Bergqvist D, Matzsch T, Brumark U et al. Low-molecular-weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988; 75: 888-91.
182. Samama M, Bernard P, Bonnardot JP et al. Low-molecular-weight heparin compared with unfractionated heparin in prevention of thrombosis. Br J Surg 1988; 75: 128-31.
183. European fraxiparin study group. Comparison of a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-63.
184. Caen JP. A randomized double-blind study between a low-molecular-weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A french multicentre trial. Thromb Haemos 1988; 59:216-20.
185. Leizorovicz A, Picolet H, Peyrieux JC et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double-blind study comparing two doses of logiparin and standard heparin. Br J Surg 1991; 78: 12-6.
186. Nurmohamed MT, Verjaeghe R, Hass S et al. A comparative trial of low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. M J Surg 1994; 169: 567-71.
187. Fletcher JP, McLellan D, Cade J, Fisher C, Gibbs H, Stacey M, Vedig A. Prevention of venous thrombo-embolism. National Working party on the prevention and management of venous thrombo-embolism and chronic venous insufficiency. Aust N Z J Surg 1999; 69: 4-5.
188. Turpie AGG, Levine MN, Hirsh J et al. A randomized controlled trial of low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-9.
189. Torholem C, Broeng L, Jorgensen PS et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: a placebo controlled study. J Bone Jt Surg Br 1991; 73 434-8.
190. Lassen MR, Borris LC, Christiansen HM et al. Prevention of thromboembolism in 190 hip arthroplasties. Acta Orthop Scand 1991; 62: 33-8.
191. Danish enoxaparin study group. Low-molecular-weight heparin (enoxaparin) vs. dextran 70. Arch Intern Med 1991; 151: 1621-4.
192. Levin MN, Hirsh J, Gent M et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-51.
193. Eriksson BI, Kalebo P, Anthmyr BA et al. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. J Bone Jt Surg Am 1991; 73: 484-93.
194. Leyvarz PF, Bachmann F, Hock J et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. Br Med J 1991; 303: 543-8.
195. Colwell CW, Spiro TE, Trowbridge AA et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Jt Surg 1994; 76: 3-14.
196. Hull RD, Raskob GE, Pineo GF et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
197. Leclerc JR, Geerts WH, Desjardins L et al. Prevention of venous thromboembolism after knee arthroplasty-a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to warfarin. Ann Intern Med 1996; 124: 619-26.
198. Leclerc JR. Low-molecular weight heparin prophylaxis in surgical patients. Clin Appl Thrombosis/Hemostasis 1997; 3: 153-6.
199. Hull RD, Brant RF, Pineo GF, Stein PD, Raskob GE, Valentine KA. Preoperative vs. postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159: 137-41.
200. Leizorovicz a, Huaugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
201. García Frade LJ. Nuevas perspectivas en tratamiento anticoagulante. Rev Iberoamer Tromb Hemostasia 1997; 10(supl. 1): 1-26.
202. Hull RD, Pineo GF. Prophylaxis of deep vein thrombosis and pulmonary embolism: current recommendations. Clin Appl Thrombosis/Hemostasis 1998; 4: 96-104.
203. AbuRahma AF, Stickler DL, Robinson PA. A prospective controlled study of the efficacy of short-term anticoagulation therapy in patients with deep vein thrombosis of the lower extremity. J Vasc Surg 1998; 28: 630-7.
204. Heilmann L, Tempelhoff GFV, Schneider D. Prevention of thrombosis in gynecologic malignancy. Clin Appl Thrombosis/Hemostasis 1998; 4: 153-59.
205. Protocolos de prevención y tratamiento de la enfermedad tromboembólica. Asociación Española de Hematología y Hemoterapia. Grupo GEHT, Sociedad Española de Trombosis y Hemostasia. Rev Iberoamer Tromb Hemostasia 1991; 6: 12-42.
206. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 1996; 27: 1698-703.
207. Nurmohamed M, Rosendaal FS, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopedic surgery: a metanalysis. Lancet 1992; 340: 152-6.
208. Carman TL, Fernández B. Issues and controversies in venous thromboembolism. Cleve Clin J Med 1999; 66: 113-23.
209. Izaguirre AR. Trombofilias secundarias. Programa Educativo. XXXIX Jornada de la AMEH 1999; 199-201.
210. Helt JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999; 159: 445-53.
211. De Groot MR, Buller HR, ten Cate JW, van Marwijk Kooy M. Use of a heparin nomogram for treatment of patients with venous thromboembolism in a community hospital. Thromb Haemost 1998; 80 70-3.
212. Whittle J, Johnson P, Localio AR. Anticoagulation therapy in patients with venous thromboembolic disease. J Gen Intern Med 1998; 13: 373-8.
213. Harensberg J, Schmitz-Huebner U, Breddin KH, Haas S, Heinrich F, Heinrich C, Kienast J, Roebruck P, Theiss W, Wenzel E. Treatment of deep vein thrombosis with low-molecular-weight heparins: A consensus statement of the Gesellschaft für Thromboseund Hämostaseforschung (GTH). Sem Thromb Hemostasia 1997; 23: 91-6.
214. Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW. Subcutaneous heparin compared with continuos intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116: 279-284.
215. Litin SC, Gastineau DA. Current concepts in anticoagulant therapy. Mayo Clin Proc 1995; 70: 266-72.
216. Rascke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight based heparin dosing nomogram compared with "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119: 874-81.
217. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.
218. Anand S, Ginsberg JS, Hirsh J. Is there a relationship between the intensity of heparin treatment and recurrent thromboembolism? Clin Appl Thrombosis/Hemostasis 1997; 3 (suppl. 1): S64 S67.
219. Campbell NR. Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Different effects of heparin in males and females. Clin Invest Med 1998; 21: 71-8.
220. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular weight heparin treatment of unstable coronary artery disease. Am Heart J 1999; 137: 72-8.
221. Mahoney MS, Kahn M. Low-molecular-weight heparin for treating venous thromboembolism. Ann intern Med 1999; 130: 77-8.
222. Quader MA, Stump LS, Sumpio BE. Low molecular weight heparins: current use and indications. J Am Coll Surg 1998; 187: 641-58.
223. Grubb NR, Bloomfield P, Ludlam CA. The end of the heparin pump? Low molecular weight heparin has many advantages over unfractionated heparin. BMJ 1998; 317: 1540-2.
224. Bratt G, Tornebohm E, Granqvist S et al. A comparison between low-molecular-weight heparin (KAB 12165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-17.
225. Holm HA, Ly B, Handeland GF et al. Subcutaneous heparin treatment of deep venous thrombosis. A comparison of unfractionated and low-molecular-weight heparin. Haemost 1986; 16: 30-7.
226. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin): results of a double-blind randomized study. Circulation 1989; 80: 935-40.
227. Bratt G, Aberg W, Johansson M et al. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (VDT). Thromb Haemost 1990; 64: 506-10.
228. Harenberg J, Huck K, Bratsch H et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemost 1990; 20 (suppl. 1): 205-19.
229. Siegbahan A, Y-Hassan S, Boberg J et al. Subcutaneous treatment of deep venous thrombosis with low-molecular-weight heparin. A dose finding study with LMWH-novo. Thromb Res 1989; 55: 267-78.
230. Bauld DL, Kovacs MJ. Dalteparin in emergency patients to prevent admission prior to investigation for venous thromboembolism. Am J Emerg Med 1999; 17: 11-5.
231. Breddin HK. Treatment of deep vein thrombosis: Is thrombosis regression a desirable endpoint? Sem Thromb Hemost 1997; 23: 179-83.
232. Meyer G, Brenot F, Pacouret G et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995; 74: 1432-5.
233. Pini M. Prevention of recurrences after deep venous thrombosis: Role of low-molecular-weight heparins. Sem Thromb Hemost 1997; 23: 51-4.
234. Monreal M. Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapy. Sem Thromb Hemost 1997; 23: 69-75.
235. Pineo GF, Hull RD, Rosenbloom D, Raskob GE. A cost-effectiveness analysis of low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. Br J Haematol 1994; 7: 184.
236. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334: 677-81.
237. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
238. Hull RD, Pineo GF, Stein P. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring. Int Angiol 1998; 17: 213-24.
239. Bergqvist D, Jendted S, Lindgren B, Matzsch T. The economics of general thromboembolic prophylaxis. World J Surg 1988; 12: 349-55.
240. Devlin JW, Petitta A, Shepard AD, Obeid FN. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 1998; 18: 1335-42.
241. Leong WA. Outpatient deep vein thrombosis treatment models. Pharmacotherapy 1998; 18: 170S-174S.
242. Evans RC, Wong VS, Morris AI, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-40.
243. Crowther M, Hirsh J. Low-molecular-weight heparin for out-of-hospital treatment of venous thrombosis: Rationale and clinical results. Sem Thrombos Hemost 1997; 23: 77-81.
244. Kessier CM. Low molecular weight heparins: practical considerations. Semin Hematol 1997; 34(suppl 4): 2-8.
245. Rodger M, Bredeson C, Wells PS. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998; 159: 931-8.
246. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Low-molecular-weight heparin versus unfractionated heparin. Haemostasis 1998; 28 (suppl 3): 8-16.
247. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM, Bick RL. The available low molecular weight heparin preparations are not the same. Clin Appl Thrombosis/Hemostasis 1997; 3(suppl 1): S38-S52.
248. Altman R. Controversies in antithrombotic therapy in cardiovascular diseases. Clin Appl Thrombosis/Hemostasis 1998; 4: 11-24.
249. Baker WF. Recommendation for antithrombotic therapy. Clin Appl Thrombosis/Hemostasis 1998; 4: 143-7.
250. Backer RC, Ball SP, Eisenberg P, Borzak S, Held AC, Spencer F, Voyce SJ, Jesse R, Handel R, Ma Y, Hurley T, Hebert J. A randomized, multicenter trial of weight adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Am Heart J 1999; 137: 59-71.
251. Kugelmass AD, Raskob GE. Antithrombotic therapy in patients undergoing coronary angioplasty or coronary stent placement. Clin Appl Thrombosis/Hemostasis 1997; 3 (suppl 1): S24-S31.
252. Popma JJ, Prpic R, Lansky AJ, Piana R. Heparin dosing in patients undergoing coronary intervention. Am J Cardiol 1998; 82: 12-24.
253. Lehmann KJ, Gonzales E, Tri BD, Vaziri ND. Systemic and translesional activation of coagulation, fibrinolytic and inhibitory system in candidates for coronary angioplasty: basal state and effect of successful dilatation. Am Heart J 1999; 137: 274-83.
254. Ragosta M, Karve M, Brezynski D, Humphries J, Senders JM. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. Am Heart J 1999; 137: 250-7.
255. Hisatomi K. Effect of low-molecular-weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats. Transplant Proc 1998; 30: 4337-9.
256. Kelly Am, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin Proc 1998; 73: 777-9.
257. Wen DY, Hasll WA. Complications of subcutaneous low-molecular-weight heparin therapy in neurosurgycal patients. Surg Neurol 1998; 50: 521-5.
258. Aburahma AF, Boland JP. Management of deep vein thrombosis of the lower extremity in pregnancy: a challenging dilemma. Am Surg 1999; 65: 164-7.
259. Thomson AJ, Walker ID, Greer IA. Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet 1998; 352: 1904.
260. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114(suppl 5): 524S-530S.
261. de Veber G, Chan A, Monagle P, Marzinotto V, Armstrong D, Massiacotte P, Leaker M, Andrew M. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol 1998; 55: 1533-7.
262. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Frequency of major complications of aspirin, warfarin and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med 1999; 130: 14-22.
263. Nurmohamed MT, van Riel AM, Henkens CMA, Koopman MMW, Que GJH, d'Azemar P, Buller HR, Tencate JW, Hock JA et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemostas 1996; 75: 233-8.
264. Sherman DG, Dyken ML, Gent M, Hamson MJG, Heart G. Antithrombotic therapy for cerebrovascular disorders. Chest 1996; 108 (suppl): 444S-56S.
265. Meillon GLA. Controversias en el tratamiento de los sindromes trombofílicos. Programa Educativo XXXIX Jornada AMEH 1999; 27-9.
266. Ruiz-Argüelles GJ. Anticoagulantes lúpicos y anticuerpos antifosfolípido. En Manual de Hemostasia y Trombosis: Martinez Murillo C, Quintana González S. Eds. Ed. Prado 1996: 351-62.
267. Ruiz-Argüelles GJ. Protein C resistence and antiphospholipid antibodies. Lupus 1996; 5: 633.
268. Ruiz-Argüelles GJ, Delezé M, Alarcón Segovia D. Correctly diagnosing a newly characterized syndrome. Am J Hematol 1991; 37: 135.
269. Alarcón-Segovia D, Delezé M, Oria CV, Sanchez-Guerrero J et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erytematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-65.
270. Alarcón-Segovia D, Sanchez Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 1989; 16: 1359-61.
271. Rojas RJ, García CM, Enríquez CG, Bañuelos RD. Síndrome de anticuerpos antifosfolípido catastrófico. Factores predictivos y prevención. Ciencia e Investig Med 1997; 5: 87-93.
272. Shulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-6.
273. Bauer A. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94-100.
274. Girolami A. Low molecular weight heparins in clinical practice: unsolved or partially solved problems. Arch Inst Cardiol Mex 1998; 68: 69-76.